Experts InSight

Antibody-drug conjugates (ADCs) are new chemotherapeutic agents that can cause significant ocular side effects. Drs. Meghan Berkenstock, Lauren Dalvin, and Stella Kim review this new class of drugs and how they can affect the eye, providing essential tips for what to look for, when to screen, and how to treat the side effects.  Prescribing information mentioned in this episode: Elahere (mirvetuximab soravtansine-gynx) Tivdak (tisotumab vedotin-tftv) For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Maura Di Nicola and Basil Williams sit down with host Dr. Jay Sridhar to review how retinoblastoma treatments have evolved, including discussion of intra-arterial and intravitreal chemotherapy and liquid biopsy using aqueous humor samples. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Dr. Mike Chiang, Dr. Michael Boland, and Kent Mathewson join host Dr. Andrew Pouw to discuss the current state of clinical documentation in ophthalmology, the future of the electronic health record (EHR), the use of scribes, and legal considerations for documentation. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Julie Falardeau and Mike Lee discuss guidelines and pearls for the management of idiopathic intracranial hypertension (IIH) during pregnancy and childbirth. They share how pregnancy shifts the evaluation and management of the initial diagnosis of IIH and how it can affect patients who already have a history of the disease. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. M. Ali Khan, Ajay Kuriyan, and Sarah Read discuss recent developments in intravitreal injectable drugs, including 8-mg aflibercept not approved by FDA, PDUFA date for on-label bevacizumab, and injections for dry AMD. They explore step therapy, biosimilars, and the impact on costs and access. They also cover treatment options and decision-making for AMD patients with geographic atrophy. A casual basketball conversation concludes the podcast.

In June 2023, the regional Medicare Administrative Contractors (MACs) almost uniformly introduced draft policy language indicating cessation of coverage for many minimally invasive glaucoma surgery (MIGS) procedures, including goniotomy and cyclophotocoagulation. In today's episode, host Andrew Pouw is joined by Dr. Alan Robin, the first executive vice president of the American Glaucoma Society, and Dr. Pradeep Ramulu, chief of the Glaucoma Division at the Johns Hopkins Wilmer Eye Institute, to discuss MACs, clinical evidence for MIGS, and advocacy efforts underway to protect patient access to MIGS procedures. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Drs. Anita Kohli and Imran Jivraj discuss the evaluation and management of patients with functional vision loss, also known as nonorganic or nonphysiologic visual loss, a phenomenon in which exam findings do not support an underlying organic etiology. Drs. Kohli and Jivraj offer pearls for how to handle both adult and pediatric patients. Functional vision loss can be challenging to identify and manage, and it's important to diagnose correctly as multiple studies have shown that there can be an association between functional vision loss and psychosocial stressors or other psychiatric diagnoses, especially among children.  For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Cornea specialist Dr. Travis Redd discusses the recent outbreak of extensively drug-resistant corneal infections associated with artificial tears and that has led to cases of permanent vision loss and death. Dr. Redd also reviews the challenges and risks of multi-use eye drop bottles. Since January 2023, the CDC, FDA, and state and local health departments have been investigating a multistate outbreak involving a rare, drug-resistant strain of Pseudomonas aeruginosa bacteria. As a result, the CDC has urged discontinued use of EzriCare Artificial Tears, and in February the FDA issued an additional warning about Delsam Pharma’s Artificial Eye Ointment. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Ophthalmic genetic counselor Molly Marra and Dr. Lesley Everett discuss the pearls and pitfalls of genetic testing, especially in cases of suspected inherited retinal dystrophy. As discussed in the episode, the National Society of Genetic Counselors offers great tools to find genetic counselors who can advise you and your patients in the diagnostic journey. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Dr. Guillermo Amescua joins host Jay Sridhar to discuss novel approaches to infectious keratitis, including surgical approaches and corneal cross-linking. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.